Acute Lymphoblastic Leukaemia
|
|
- Simon Brian Greene
- 7 years ago
- Views:
Transcription
1 1 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Protocol Acute Lymphoblastic Leukaemia Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma UKALL 2011 (<25years) Regimen A induction consolidation Protocol M Interim MX 1 Delayed intensification Day 1-28 Delayed intensification Day Maintenance Regimen B induction BFM consolidation Interim MX 1 Protocol M Delayed intensification Day 1-28 Delayed intensification Day Maintenance Regimen C induction (low risk) POSCU Level 2 POSCU Level 3 Brighton Vincristine,Pegaspargase, Dexamethasone vincristine vincristine vincristine vincristine Mercaptopurine, mercaptopurine, methotrexate Vincristine, mercaptopurine, MTX, dexamethasone Vincristine, Doxorubicin Dexamethasone, Pegaspargase, dexamethasone dexamethasone dexamethasone dexamethasone dexamethasone cyclophosphamide, cytarabine, mercaptopurine cytarabine Vincristine, mercaptopurine, MTX, dexamethasone dexamethasone Vincristine,Pegaspargase, Dexamethasone Daunorubicin vincristine Cyclophosphamide, cytarabine, Mercaptopurine cytarabine Vincristine, 6 MP, MTX, dexamethasone dexamethasone mercaptopurine, methotrexate Vincristine, Doxorubicin Dexamethasone,pegaspargase, cyclophosphamide, cytarabine, dexamethasone daunorubicin cytarabine and cyclophosphamide dexamethasone dexamethasone daunorubicin cytarabine and cyclophosphamide dexamethasone dexamethasone daunorubicin cytarabine and cyclophosphamide dexamethasone dexamethasone 6MP cytarabine Vincristine, 6 MP, MTX, dexamethasone dexamethasone Vincristine,Pegaspargase, Dexamethasone Daunorubicin vincristine dexamethasone daunorubicin dexamethasone daunorubicin dexamethasone daunorubicin
2 2 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 augmented BFM consolidation Day 1-28 augmented BFM consolidation Day Escalating Capizzi MTX Day 1, 12, 22, 32, 42 Protocol M-A Delayed intensification Day 1-28 Delayed intensification Day Maintenance Itrathecal MTX Vincristine, Pegaspargase Cyclophosphamide, cytarabine, Mercaptopurine Cyclophosphamide, cytarabine, Mercaptopurine Vincristine, Pegaspagase Vincristine, Methotrexate, cytarabine cytarabine Pegaspargase vincristine mercaptopurine, methotrexate pegaspargase Vincristine, Doxorubicin Dexamethasone, Pegaspargase, Cyclophosphamide, 6MP, Cytarabine, Vincristine dexamethasone Pegaspargase cytarabine Vincristine, Dexamethasone, 6 MP, MTX Protocol Relapsed Acute Lymphoblastic leukaemia IntReALL 2010 (Phase III) trial - once this is available POSCU Level 1 (low risk) POSCU Level 2 POSCU Level 3 Brighton Relapsed ALL treatment guidelines (NB Clofarabine funded by CDF) Phase 1 Induction - standard and Vincristine, Dexamethasone intermediate risk Mitoxantrone, Pegaspargase or Weeks 1-4 Induction - high risk Weeks 1-4 Phase 2 Erwinia asparaginase Clofarabine, Etoposide Cyclophosphamide, Dexamethasone, Pegaspargase or Erwinia asparaginase
3 3 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Consolidation - all risks Week 5 Vincristine, Dexamethasone Consolidation - all risks Week 6 Consolidation - standard and intermediate risk MTX, pegaspagase or erwinia asparaginase Week 7 etoposide, cyclophosphamide Consolidation - High risk Week 7 Consolidation - High risk Vincristine, Dexamethasone, Pegaspargase or Erwinia asparaginase, Mitoxantrone Week 8 Vincristine Consolidation - High risk Week 9 Phase 3 Intensification -standard and intermediate risk Vincristine, Dexamethasone, Pegaspargase or Erwinia asparaginase, Erwinia Asparaginase, dexamethasone, cytarabine, vincristine week 9 Intensification - standard and intermediate risk week 10 Erwinia Asparaginase, cytarabine Intensification - standard and intermediate risk week 12 Intensification - high risk week 11 MTX, Erwinia Erwinia Asparaginase, dexamethasone, cytarabine, vincristine Intensification - high risk week 12 Erwinia Asparaginase, cytarabine Intensification - high risk week 14 Phase 4 All risks - FLAD Phase 5 MTX, Erwinia Fludarabine, Cytarabine Daunoxome IM with CNS irradiation all risks week 14 Dexamethasone, 6MP, Vincristine,
4 4 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 week 17 6MP,MTX week 20 Etoposide, cyclophosphamide, Cytarabine, MTX Tioguanine cytarabine cytarabine Etoposide, cyclophopshamide, week 21 cytarabine cytarabine cytarabine Dexamethasone, 6MP, MTX, week 22 Vincristine week 25 6MP,MTX week 28 week 29 IM no CNS irradiation Etoposide, cyclophosphamide, Cytarabine, MTX Tioguanine cytarabine cytarabine Etoposide, cyclophopshamide, cytarabine cytarabine cytarabine all risks week 14 Dexamethasone, 6MP, Vincristine, week 20 week 21 week 22 week 28 week 29 Phase 6 maintenance Etoposide, cyclophosphamide, Cytarabine, MTX Tioguanine cytarabine cytarabine Etoposide, cyclophopshamide, cytarabine cytarabine cytarabine Dexamethasone, 6MP, MTX, Vincristine Etoposide, cyclophosphamide, Cytarabine, MTX Tioguanine cytarabine cytarabine Etoposide, cyclophopshamide, cytarabine cytarabine cytarabine courses 1-7 vincristine, dexamethasone 6MP MTX course 8 vincristine, dexamethasone 6MP MTX intrathecal Refractory ALL FLAG Fludarabine, Cytarabine FLAG-IDA Fludarabine, Cytarabine Idarubicin Clorafabine - single agent Clofarabine
5 5 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Clorafabine, Etoposide, Cyclophosphamide Clorafabine, Etoposide, Cyclophosphamide Protocol Ph+ve Acute Lymphoblastic Leukaemia EsPhALL guidelines (imatinib funded by CDF) Phase 1B Induction Day 1-29 Consolidation Block 1 Consolidation block 2 Cyclophosphamide 6MP, imatinib, cytarabine MTX, dexamethasone, vincristine, cyclophosphamide, cytarabine, pegasparagase, imatinib dexamethasone, MTX, vindesine, ifosfamide, Daunorubicin, Pegaspargase, imatinib dexamethasone cytarabine Consolidation block 3 etoposide, pegaspargase, imatinib Imatinib - continuation imatinib Intrathecal therapy UKALL R3 +/- Imatinib for details see under ALL (low risk) POSCU Level 2 POSCU Level 3 Brighton Protocol Acute Myeloid Leukaemia Treatment guidelines for AML and high Risk MDS in Children <16years (exc APL and Downs syndrome) ADE ADE Etoposide, Cytarabine, Daunorubicin Etoposide, Cytarabine, Daunorubicin Course 3 CYTARABINE Cytarabine Course 4 CYTARABINE Cytarabine FLAG-IDA Fludarabine, Cytarabine, Idarubicin (low risk) POSCU Level 2 POSCU Level 3 Brighton
6 6 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 TRIPLE IINTRATHECAL CHEMOTHERAPY Methotrexate, Cytarabine, Hydrocortisone AML 17 trial for young adults >18years (mylotarg funding agreed at RMH as currently no national funding stream) ADE ADE mylotarg DA 3+10+mylotarg ADE ADE mylotarg (for CBF patients who didn't receive mylotarg in course 1 ) Etoposide, Cytarabine, Daunorubicin Etoposide, Cytarabine, Daunorubicin, Gemtuzumab Ozogamicin Cytarabine, Daunorubicin, Gemtuzumab Ozogamicin Etoposide, Cytarabine, Daunorubicin Etoposide, Cytarabine, Daunorubicin, Gemtuzumab Ozogamicin Course 3 CYTARABINE Cytarabine Course 4 CYTARABINE Cytarabine FLAG-IDA Fludarabine, Cytarabine, Idarubicin CLOFARABINE and DAUNORUBICIN Clofarabine, Daunorubicin TRIPLE IINTRATHECAL CHEMOTHERAPY Methotrexate, Cytarabine, Hydrocortisone Acute Myeloid Leukaemia - Relapsed (based on guidelines from Brenda Gibson 2010) FLA Cytarabine, Fludarabine FLAG-X Cytarabine, Fludarabine, DaunoXome FLA-IDA Fludarabine, Cytarabine Idarubicin CYTARABINE ETOPOSIDE BFM schedule Cytarabine, Etoposide HIDAC Cytarabine Cytarabine, methotrexate, Intrathecal Triple hydrocortisone
7 7 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Refractory Acute Myeloid Leukaemia - guidelines FLAG Fludarabine, Cytarabine FLAG-IDA Fludarabine, Cytarabine Idarubicin Relapsed and Refractory Flt-3 ITD positive AML (Clofarabine funded by CDF) Clofarabine, Cyclophosphamide, Etoposide Clofarabine, Cyclophosphamide, Etoposide other options for relapsed AML Methotrexate Pegaspargase Methotrexate Pegaspargase L6 tioguanine, cytarabine FLAMSA RIC Amsacrine, Cytarabine Fludarabine, busulfan, cyclophosphamide, ATG AML guidelines for Downs Syndrome ML-DS 2007 AIE Cytarabine Idarubicin Etoposide AI Cytarabine Idarubicin ham Cytarabine Mitoxantrone HA Cytarabine Protocol Acute Pro-myelocytic Leukaemia Acute Promyelocytic Leukaemia - guidelines (low risk) POSCU Level 2 POSCU Level 3 Brighton Induction - standard ATRA, idarubicin induction - high risk ATRA, idarubicin Consolidation 1 ATRA, idarubicin, mitoxantrone consolidation 2 ATRA, idarubicin consolidation 3 ATRA, idarubicin, cytarabine maintenance cycle 1 6MP, MTX maintenance cycle 2 ATRA, 6MP, MTX
8 8 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 intrathecal therapy Acute Promyelocytic Leukaemia (relapsed) - guidelines (mylotarg needs IFR approval) ATO arsenic trioxide ATRA tretinoin GO gemtuzumab ozogamicin Acute Promyelocytic Leukaemia (CNS relapsed) - guidelines induction consolidation 3rd line gemtuzumab ozogamicin, cytarabine, tretinoin, gemtuzumab ozogamicin, cytarabine, tretinoin, FLAG-IDA Fludarabine, Cytarabine Idarubicin FLAG-DaunoXome Cytarabine, Fludarabine, DaunoXome Protocol Chronic Myeloid Leukaemia Ph +ve Chronic Myeloid Leukaemia - guidelines (imatinib funded by NICE) Imatinib Imatinib Hydroxycarbamide Hydroxycarbamide Dasatinib ALL induction- see UKALL 2011 FLAG See ALL Juvenile Myelomonocytic Leukaemia (JMML) - guidelines Cytarabine, Etoposide 6MP, tretinoin 2nd line use AML guidelines (low risk) POSCU Level 2 POSCU Level 3 Brighton
9 9 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Protocol B-cell Non Hodgkin s Lymphoma (low risk) POSCU Level 2 POSCU Level 3 Brighton High Risk patients Intergroup Rituximab trial B-NHL CCLG guidelines - 1st line Group A Cyclophosphamide, Doxorubicin, COPAD Vincristine, Prednisolone Group B Cyclophosphamide, Prednisolone, COP COPADM 1+2 CYM 1+2 Group C COP COPADM 1 COPADM 2 Vincristine Cyclophosphamide, Prednisolone, Vincristine, Doxorubicin, Methotrexate Cytarabine, methotrexate Cyclophosphamide, Prednisolone, Vincristine Cyclophosphamide, Prednisolone, Vincristine, Doxorubicin, Methotrexate Cyclophosphamide, Prednisolone, Vincristine, Doxorubicin, methotrexate CYVE 1+2 Cytarabine, Etoposide HD-MTX Maintenance C1 Methotrexate vincristine,prednisolone, methotrexate, cyclophosphamide, doxorubicin Maintenance C 2+4 cytarabine, etoposide vincristine, prednisolone, Maintenance C3 cyclophosphamide, doxorubicin Rituximab Rituximab Intrathecal Treatment MTX and HYD Methotrexate, hydrocortisone CYT and HYD Cytarabine, hydrocortisone Triple Methotrexate, hydrocortisone,
10 10 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 cytarabine B-NHL 2nd Line - guidelines CYVE Cytarabine, Etoposide ICE Ifosfamide, Cytarabine, Etoposide Rituximab rituximab carmustine,melphalan, etoposide, BEAM cytarabine RMH Primary Mediastinal Large Cell NHL see inter B-NHL trial guidelines R-EPOCH Lymphoproliferative disease Rituximab, prednisolone, Etoposide, Doxorubicin, Vincristine Cyclophosphamide RMH Rituximab Rituximab R-COP Rituximab, Cyclophosphamide, Vincristine, Doxorubicin see also see B-NHL guidelines- modified for according to organ damage Protocol Acute Lymphoblastic Lymphoma UKALL 2011 please refer to ALL section Lymphoblastic lymphomas - Relapsed/Refractory 2nd line please refer to UKALL R3 protocol under ALL relapsed section Lymphoblastic lymphomas - Relapsed/Refractory 3rd line (Nelarabine funding via CDF) FLAG Fludarabine, Cytarabine, GCSF FLAG - IDA Nelarabine, Cyclophosphamide, Etoposide Fludarabine, Cytarabine, GCSF, Idarubicin Nelarabine, Cyclophosphamide, Etoposide (low risk) POSCU Level 2 POSCU Level 3 Brighton
11 11 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Protocol Anaplastic Large Cell Lymphoma Anaplastic Large Cell Lymphoma - ALCL CCLG guidelines Pre-course P Course AM Course A Course BM Course B Intrathecal cyclophosphamide, dexamethasone, Methotrexate, ifosfamide, cytarabine, etoposide dexamethasone, ifosfamide, methotrexate, cytarabine, etoposide Methotrexate, Dexamethasone, Cyclophosphamide, doxorubicin Methotrexate, Dexamethasone, Cyclophosphamide, doxorubicin Methotrexate, Cytarabine, hydrocortisone Anaplastic Large Cell lymphomas - relapsed guidelines CC ICM ICI dexamethasone, (low risk) POSCU Level 2 POSCU Level 3 Brighton vindesine,cytarabine, etoposide, mitoxantrone, carboplatin, ifosfamide, Idarubicin, carboplatin, ifosfamide, Lomustine, Vinblastine, CVA Cytarabine V vinblastine BEAM Thio/Eto/Bu/ATG Melphalan, Carmustine, Cytarabine, etoposide RMH Thiotepa, Etoposide, Busulfan, ATG, RMH Anaplastic Large Cell lymphomas - relapsed 3rd line Vinblastine Vinblastine
12 12 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Protocol Hodgkin s Lymphoma Hodgkin s disease - Euronet protocol OEPA COPP Vincristine etoposide (low risk) POSCU Level 2 POSCU Level 3 Brighton prednisolone, doxorubicin Vincristine Cyclophosphamide, prednisolone, procarbazine, vincristine Vincristine COPDAC vincristine, dacarbazine, cyclophosphamide, prednisolone, Vincristine Hodgkins disease - Relapsed protocol Ifosfamide, etoposide, IEP Prednisolone ABVD EPIC D1-5 Doxorubicin, Vinblastine, Bleomycin, dacarbazine Ifosfamide, etoposide, Prednisolone EPIC D10 Cisplatin Carmustine, Etoposide, BEAM Cytarabine, Melphalan RMH Hodgkin s disease - 3rd line (Brentuximab funding via CDF) GEM-P gemcitabine, cisplatin, +/- dexamethasone Brentuximab Brentuximab Hodgkins disease - 4th line Vinblastine (as per ALCL) Vinblastine Lymphocyte Predominant Hodgkins disease CVP OEPA vinblastine, prednisolone, cyclophosphamide Vincristine, etoposide prednisolone, doxorubicin Vincristine Vincristine
13 13 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Protocol Neuroblastoma Localised Unresectable neuroblastoma (CCLG guidelines) (low risk ) POSCU Level 2 POSCU Level 3 Brighton Carbo-Etoposide Carboplatin, Etoposide CADO Cyclophosphamide, Doxorubicin, Vincristine Irinotecan-TMZ Irinotecan, temozolomide Localised Unresectable neuroblastoma - relapsed Cisplatin-Etoposide Cisplatin, etoposide cyclo-topotecan Cyclophosphamide, topotecan High risk Neuroblastoma HR-NBL trial (open to recruitment) Rapid COJEC D0 and 40 Vincristine Carboplatin etoposide Rapid COJEC D10,30,50,70 Vincristine, Cisplatin Rapid COJEC 20,60 Cyclophosphamide Etoposide Cyclophosphamide, Vincristine N7-CAV Doxorubicin N7-PE Cisplatin, etoposide TVD Topotecan, Vincristine Doxorubicin Bu-Mel Busulfan, Melphalan RMH isotretinoin isotretinoin anti GD2 antibody RMH Neuroblastoma - Refractory after HR-NBL and 2nd line therapies TVD Topotecan, Vincristine Doxorubicin Irinotecan-TMZ Irinotecan, temozolomide cyclo-topotecan Cyclophosphamide, topotecan Cyclo-Etoposide oral Cyclophosphamide Etoposide Neuroblastoma - 3rd line Topotecan with mibg Topotecan Opsoclonus myoclonus (OMS/DES 2011) Dexamethasone, Cyclophosphamide Dexamethasone, Cyclophosphamide
14 14 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Protocol Ewings Sarcoma (low risk ) POSCU Level 2 POSCU Level 3 Brighton Ewings Sarcoma - Euro-Ewings 2012 trial (includes metastatic disease) Vincristine, Ifosfamide, Etoposide, VIDE Doxorubicin VAI Vincristine, Ifosfamide, actinomycin D Vincristine. Actinomycin D VAC Cyclophosphamide Bu-Mel busulfan, melphalan RMH VCD Vincristine, Cyclophosphamide, Doxorubicin VC Vincristine, Cyclophosphamide IE Ifosfamide, Etoposide Ewings sarcoma - relapsed TMZ-IRINO Temozolomide, Irinotecan Protocol Rhabdomyosarcoma EpSSG RMS 2005 trial (includes metastatic disease) IVADO CVADO Ifosfamide, Vincristine, Actinomycin (low risk ) POSCU Level 2 POSCU Level 3 Brighton D, Doxorubicin Cyclophosphamide Vincristine, Actinomycin D, Doxorubicin Cyclophosphamide Vincristine, CVA Actinomycin D, Ifosfamide, Vincristine, Actinomycin IVA D, VA Vincristine, actinomycin D Vincristine Vinorelbine-Cyclo rhabdomyosarcoma - second line therapy
15 15 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Topo-Cyclo Topotecan, cyclophosphamide Topo-Carbo Topotecan, carboplatin Etop-Carbo Etoposide, Carboplatin Dox- Carbo Doxorubicin, Carboplatin Dox- Cyclo Doxorubicin, Cyclophosphamide rhabdomyosarcoma relapsed (trial currently open) Vincristine, Irinotecan +/- VI(T) Temozolomide Proforma Wilms tumour Wilms tumour WT 2001 trial (closed) (low risk ) POSCU Level 2 POSCU Level 3 Brighton AVD Actinomycin D, Vincristine Doxorubicin AV-1 Actinomycin D, Vincristine AV-2 Actinomycin D, Vincristine V vincristine etop-carb Etoposide, Carboplatin cyclo-dox cyclophospamide, doxorubicin Wilms tumour relapsed - CCLG guidelines Group B - Course 1 cyclophosphamide, etoposide Group B - Course 2 cyclophosphamide, doxorubicin Group C- Course 1 Carboplatin, Etoposide Group C - Course 2 Cyclophosphamide, Etoposide Melphalan-PBSC Melphalan ICE Ifosfamide, Carboplatin, Etoposide Topotecan Topotecan Clear cell Sarcoma of Kidney (CCSK) - see recommendations in WT 2001 Stage I-III AVA Actinomycin D, Doxorubicin, Vincristine Stage I-III V Vincristine Stage IV - see high risk post-op arm of Wilms
16 16 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Standard risk - SIOPEL 6 Protocol Hepatoblastoma (low risk ) POSCU Level 2 POSCU Level 3 Brighton Cisplatin Cisplatin Hepatoblastoma - High risk (superplado) Carbo/Dox Carboplatin Doxorubicin Cisplatin Cisplatin Hepatoblastoma - Very High risk SIOPEL 4 guidelines Block A1- Day 1 Cisplatin Block A1 - day 8-9 Cisplatin, Doxorubicin Block A1- day 15 Cisplatin Block A2 - day 29 Cisplatin Block A2 - day Cisplatin, Doxorubicin Block A2 - day 43 Cisplatin Block A3 - day Cisplatin, Doxorubicin Block A3 - day 64 Cisplatin Block B Carboplatin, Doxorubicin Block C Carboplatin, Doxorubicin Hepatocellular Carcinoma - SIOPEL 5 guidelines (Thalidomide funded at RMH by local agreement) Cisplatin- Dox Cisplatin, Doxorubicin Thalidomide- Cyclo Thalidomide, oral cyclophosphamide Hepatoblastoma - relapsed and refractory Irinotecan Irinotecan Docetaxel Docetaxel Hepatoblastoma - relapsed and refractory Irinotecan Irinotecan
17 17 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Protocol Soft Tissue Sarcomas (low risk ) POSCU Level 2 POSCU Level 3 Brighton EpSSG NRSTS trial (open trial) Ifos-Dox Ifosfamide, Doxorubicin Vin- Cyclo oral Vinorelbine, Cyclophosphamide Vinorelbine oral Vinorelbine Extracranial rhabdoid tumours - EpSSG NRSTS VDCy Vincristine, Doxorubicin, Cyclophosphamide Cy*CE Carboplatin, Cyclophosphamide, Etoposide Aggressive fibromatosis - EpSSG NRSTS vinblastine, methotrexate IVA Ifosfamide Vincristine ActinomycinD VA Vincristine, actinomycin D tamoxifen Tamoxifen Protocol Rare Tumours (low risk ) POSCU Level 2 POSCU Level 3 Brighton Adrenal - ACT guidelines CCLG 1st line Mitotane, Cisplatin, Etoposide 2nd line Mitotane, Gemcitabine, Docetaxel, 5FU Germ cell tumour CCLG guidelines JEB Carboplatin, Etoposide, bleomycin Urology/gynaecology unit guidelines RMH BEP Cisplatin, Etoposide, Bleomycin Germ cell tumour - relapsed CCLG guidelines VEIP Vinblastine, Ifosfamide, Cisplatin, Pac/Cis/ Gem Paclitaxel, Cisplatin, Gemcitabine Naso-pharyngeal Carcinoma (CCLG guidelines) Cisplatin, 5FU,
18 18 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Langerhans Cell Histiocytosis (LCH III) Group 1: multi-system "Risk" Patients treatment arm A Course 1 prednisolone, vinblastine Course 2 prednisolone, vinblastine Continuation 6MP, prednisolone, vinblastine treatment arm B course 1 prednisolone, vinblastine, MTX course 2 prednisolone, vinblastine, MTX Continuation prednisolone, vinblastine, po MTX Group 2: low "Risk" Patients course 1 prednisolone, vinblastine course 2 prednisolone, vinblastine continuation prednisolone, vinblastine Group 3: "multifocal bone disease" and "special" site" Initial treatment prednisolone, vinblastine Continuation prednisolone, vinblastine Pleuropulmonary blastoma IVADo Ifosfamide, Vincristine, Actinomycin D, Doxorubicin IVA Ifosfamide, Vincristine, Actinomycin D, Pancreatoblastoma (CCLG guidelines) PLADO cisplatin doxorubicin Proforma Palliative Chemotherapy (low risk ) POSCU Level 2 POSCU Level 3 Brighton Relapsed and refractory solid tumours Cyclo- Etoposide Cyclophosphamide, Etoposide 3x3 Cyclophosphamide, Etoposide 21 day Etoposide Etoposide
19 19 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Protocol Brain Tumours POSCU Level 1 (low risk) POSCU Level 2 POSCU Level 3 Brighton Low grade gliomas SIOP LGG 2004 trial (now closed but used as guideline) Standard Induction VC Vincristine, Carboplatin Standard induction V Vincristine Consolidation V Vincristine Consolidation VC Vincristine, Carboplatin Consolidation Vcyc Vincristine cyclophosphamide Consolidation Vcis Vincristine Cisplatin Vinblastine Vinblastine Low Grade Gliomas - Relapsed Vinblastine TPCV Tioguanine, Procarbazine, Lomustine Vincristine TMZ Temozolomide subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (IFR funding required) Everolimus Everolimus High Grade Gliomas >3years - CCLG + NICE guidelines TMZ Temozolomide TMZ+DXT Temozolomide High Grade Gliomas <3years - SIOP Infant HGG study High Grade Glioma - Relapsed PCV Procarbazine, Lomustine, Vincristine Lomustine single agent (if unable to tolerate PCV) lomustine Oligodendroglioma guidelines PCV Procarbazine, Lomustine, Vincristine > 3 years Standard risk medulloblastoma PNET5 or ACNS0331 (COG) - off study Regimen B' vincristine, cyclophosphamide vincristine (with DXT) Regimen A' Lomustine, Vincristine Cisplatin vincristine vincristine
20 20 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 < 3 years Standard risk medulloblastoma (Guidelines) modified' headstart 2 Vincristine, Cisplatin, Methotrexate, cyclophosphamide, etoposide <3 years High Risk PNET (medulloblastoma) guidelines modified' headstart 2 Vincristine, Cisplatin, Methotrexate, cyclophosphamide, etoposide high dose MTX at RMH high dose MTX at RMH Carboplatin, Etoposide Thiotepa >3 years High Risk PNET (medulloblastoma) guidelines Vincristine, Carboplatin (with Radiotherapy) Vincristine, Carboplatin vincristine, cyclophosphamide relapsed PNET (Milan protocol) Induction Vinc/MTX Vincristine, Methotrexate high dose MTX at Induction Etopophos Induction Cyclo/Vinc Induction Carbo/Vinc Etoposide Phosphate Vincristine, cyclophosphamide Carboplatin, Vincristine RMH High dosethiotepa etoposide conditioning Thiotepa Etoposide High dosethiotepa conditioning Thiotepa sequential Cyclo- Etoposide orally Cyclophosphamide, Etoposide Other options (IFR/co-payment funding application necessary) Bevacizumab Temozolomide irinotecan Bevacizumab, Temozolomide, irinotecan Depocyte (intrathecal) Pineoblastoma - treat as high risk PNET guidelines Ependymoma ("Baby Brain" guidelines) Course 1 Vincristine, Carboplatin Course 2 Methotrexate high dose MTX at RMH Course 3 Vincristine cyclophosphamide
21 21 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Course 4 Cisplatin x2 Ependymoma relapsed (thalidomide funded by internal RMH agreement) Etoposide Etoposide Dana-Farber' regimen thalidomide, Cyclophosphamide, Etoposide, Celecoxib Choroid Plexus tumours ICE Ifosfamide, carboplatin, etoposide Choroid Plexus tumours - relapsed/ refractory Temozolomide Temozolomide Intracranial SIOP germ cell tumour (GCT II) PEI Cisplatin, Etoposide, Ifosfamide PEI (High dose) Cisplatin, Etoposide, Ifosfamide Carbo-PEI cycle 1+3 Carboplatin, Etoposide Carbo-PEI cycle 2+4 ifosfamide, etoposide Atypical teratoid rhabdoid tumour (ATRT) <3years modified' headstart 2 Vincristine, Cisplatin, Methotrexate, cyclophosphamide, etoposide high dose MTX at RMH Carbopatin, Etoposide Thiotepa Atypical teratoid rhabdoid tumour (ATRT) >3years - treat as High risk PNET or High risk sarcoma Choroid plexus carcinoma ICE Ifosfamide, carboplatin., etoposide Palliative chemotherapy (thalidomide funded by internal RMH agreement) Dana-Farber' regimen Thalidomide thalidomide, Cyclophosphamide, Etoposide, Celecoxib sequential Cyclo- Etoposide Cyclophosphamide, Etoposide 3x3' oral Cyclophosphamide, Etoposide Etoposide 21 day oral Etoposide Cyclophosphamide 21 day oral Cyclophosphamide
22 22 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Diagnosis Transplant Conditioning regimens POSCU Level 1 (low risk) POSCU Level 2 POSCU Level 3 Brighton ATG ATG (Rabbit) Cyclo prime Cyclophosphamide Busulfan Busulfan IV Fludarabine, Alemtuzumab, Cyclophosphamide Fludarabine, Busulfan Fludarabine, Melphalan, Alemtuzumab Fludarabine, Cyclophosphamide Etopophos Thiotepa, Etopophos Busulfan po Busulfan, Alemtuzumab, Cyclophosphamide Busulfan, Melphalan Cyclophosphamide Cyclophosphamide, Busulfan fludarabine Hydration post stem cell infusion Busulfan, melphalan, Cyclophosphamide, Alemtuzumab Melphalan-PBSC Melphalan
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
More informationMedications most likely to be seen in primary care
Hazardous Medicines The majority of medicines are not classed as hazardous. The only medicinal products that are automatically deemed to be hazardous are cytotoxic and cytostatic medicines. There is no
More informationHydration, IV Infusions, Injections and Vaccine Charge Process
There are a number of items to be considered when billing for the Nursing service to perform drug therapy, the charge process is divided into three specific groups of codes and processes. 1. Hydration
More informationA guide to cancer types and chemotherapy medications
A guide to cancer types and chemotherapy medications This guides lists words that mean cancer, cancer types and intravenous chemotherapy medications. If you have any questions, see page 10 for details
More informationPan Birmingham Cancer Network: Haematology NSSG Chemotherapy Regimens AML intensive v1.0 August 2010
AML - TRIALS It is best practise for all patients to be treated on the appropriate NCRI national trial for AML. It is outside of the remit for this regimen list to provide a comprehensive detail of the
More informationChapter 7: Lung Cancer
Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin
More informationPediatric Oncology for Otolaryngologists
Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department
More informationPreventing and Treating Nausea and Vomiting Caused by Cancer Treatment
A Patient s Guide Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment Recommendations of the American Society of Clinical Oncology The American Society of Clinical Oncology (ASCO) is
More informationCHEMOTHERAPY PROTOCOLS V10.1
CHEMOTHERAPY PROTOCOLS V10.1 Issue Date: 10 th July 2014 Page 1 of 42 Filename: MCHACPROTO Issue No: 10.1 CCC Chemotherapy Protocols Haematological Malignancies... 3 Hodgkins disease...3 Non-Hodgkins Lymphoma...5
More information2014-06-10 Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy 2014-05-
Sub. Sub. Status -06-16 Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib -06-16 Approved Lenalidomide - 2nd line treatment
More informationGuidelines for the Management of. Nausea and Vomiting in Cancer Patients
Guidelines for the Management of Nausea and Vomiting in Cancer Patients Guidelines for the Management of Nausea and Vomiting in Cancer Patients Management of chemotherapy-induced nausea and vomiting includes
More informationMASCC/ESMO Antiemetic Guideline 2013
MASCC/ESMO Antiemetic Guideline 2013 Multinational Association of Supportive Care in Cancer Organizing and Overall Meeting Chairs: Richard J. Gralla, MD Fausto Roila, MD Maurizio Tonato, MD Jørn Herrstedt,
More informationTHE HAZARDOUS WASTE (ENGLAND AND WALES) REGULATIONS 2005
THE HAZARDOUS WASTE (ENGLAND AND WALES) REGULATIONS 2005 Interim Guidance for the NHS Hospital Sector for England and Wales and Information for Scotland Additional paper copies may be requested by contacting:
More informationCost Differences in Cancer Care Across Settings
Cost Differences in Cancer Care Across Settings August 2013 THE MORAN COMPANY 1 Cost Differences in Cancer Care Across Settings In a prior memorandum, we presented evidence documenting the growing share
More informationGROUP 1 CARCINOGEN, CHEMOTHERAPY WASTE & OTHER HAZARDOUS DRUG DISPOSAL NAME APPROVAL DATE EFFECTIVE DATE REVISION RENEE MICHEL 05/01/11 0
GROUP 1 CARCINOGEN, CHEMOTHERAPY WASTE & OTHER HAZARDOUS DRUG DISPOSAL NAME APPROVAL DATE EFFECTIVE DATE REVISION RENEE MICHEL 05/01/11 0 INTRODUCTION Prior to commencing work involving carcinogens, chemotherapeutics
More informationAntiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy
Antiemetic Guidelines f Adult Patients Receiving Chemotherapy and Radiotherapy Produced by Pinkie Chambers and Susanna Daniels University College Hospital NHS Foundation Trust November 2010 (Review date
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationCancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationMEDICAL CENTER ADMINISTRATIVE POLICY AND PROCEDURES SCOPE KFH Hospital, City Section No.
of 22 I. Purpose To establish safe medication practices for High Alert medications to maximize the safety of the medication processes associated with these medications. II. Policy. High alert medications
More informationStakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy
Brochure More information from http://www.researchandmarkets.com/reports/1088137/ Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Description: The drug therapy of acute
More informationOverview: 1. Epidemiology of childhood cancer survivorship 2. Late effects 3. Palliative care of survivors 4. Examples
Childhood Cancer Survivorship Jacqueline Casillas, M.D., M.S.H.S. Associate Program Director of the UCLA-LIVESTRONG LIVESTRONGTM TM Center of Excellence for Survivorship Care Overview: 1. Epidemiology
More informationClinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. April 2013. Reference: NHSCB/B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation First published:
More informationCycle frequency: Every four weeks Total number of cycles: 6-8
Fludarabine Low Grade non-hodgkin s Lymphoma and CLL Fludarabine 25mg/m 2 oral Days 1-5 Cycle frequency: Every four weeks Total number of cycles: 6-8 Anti-emetic group Low Prophylactic co-trimoxazole and
More informationAbout chemotherapy for lung cancer
About chemotherapy for lung cancer This information is about chemotherapy for lung cancer. There are sections on What is chemotherapy? Chemotherapy for small cell lung cancer Chemotherapy for non-small
More informationNational Cancer Drugs Fund List (Updated 13 February 2014)
National Cancer Drugs Fund List (Updated 13 February 2014) DRUG Abiraterone Aflibercept Axitinib Bendamustine NCDF APPROVED CRITERIA The treatment of metastatic castration resistant prostate cancer where
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More informationHematologic Malignancies
C O N N E C T I N G L I F E A N D S C I E N C E Hematologic Malignancies Issue Number 7 Spring 2010 Myelodysplastic Syndromes Peter Westervelt, M.D., Ph.D., Associate Professor of Medicine Chief, Section
More informationTrials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
More informationBRAIN CANCER TREATMENT REGIMENS (Part 1 of 5)
BRAIN CANCER TREATMENT REGIMENS (Part 1 of 5) The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationClinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment
Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment Reference: NHS England xxx/x/x 1 Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy)
More informationLeukaemia and lymphoma what s the difference?
Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.uk Leukaemia and lymphoma what s the difference? This is a difficult question to answer simply but it is one that is often
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress Rescue Chemotherapy Protocols for Dogs with Lymphoma Kenneth M. Rassnick, DVM, DACVIM (Oncology) Cornell University
More informationOncologic drug Exposure Risks and Prevention Guidelines 19 June 2014
Oncologic drug Exposure Risks and Prevention Guidelines 19 June 2014 ส งค กคามซ งอาจเป นอ นตรายต อส ขภาพ HAZARD? HAZARD ส งค กคามซ งอาจเป นอ นตรายต อส ขภาพ ENCLOSURE Substitution ส งค กคามซ งอาจเป นอ นตรายต
More informationCarcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition, 2001 Vagina Jeffrey L. Stern, MD Carcinoma of the vagina is
More informationPRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including anaplastic, gliosarcoma and glioblastoma multiforme)
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including
More informationSmall-Cell Lung Cancer: Is There a Standard Therapy?
Small-Cell Lung Cancer: Is There a Standard Therapy? Review Article [1] January 02, 1998 By Pieter E. Postmus, MD, PhD [2] and Egbert F. Smit, MD [3] For more than 25 years, chemotherapy has been the cornerstone
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationMALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationNon-Hodgkin Lymphoma Richard Orlowski, MD
Non-Hodgkin Lymphoma Richard Orlowski, MD The American Cancer Society (ACS) estimates that 69,740 Americans will be diagnosed with non-hodgkin lymphoma (NHL) in 2013. Excluding non-melanoma skin cancers,
More informationAcute Myelogenous Leukemia: A Guide for Patients and Caregivers
Acute Myelogenous Leukemia: A Guide for Patients and Caregivers LE UK E M I A Printing of this publication made possible by an education grant from LYMPHOMA M Y E L OM A Introduction Table of Contents
More informationCollaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY
Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular
More informationa nonprofit organization Cancer & Fertility Fast Facts for Oncology Professionals information support hope
a nonprofit organization Cancer & Fertility Fast Facts for Oncology Professionals information support hope table of contents introduction 1 male patients risks 2 options 2 female patients risks 6 options
More informationTreating myeloma. Dr Rachel Hall Royal Bournemouth Hospital
Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens
More informationHaematopoietic stem cell transplantation in Hong Kong
S C I E N T I F I C P A P E R Haematopoietic stem cell transplantation in Hong Kong Albert KW Lie WY Au Raymond Liang 李 國 維 區 永 仁 梁 憲 孫 The first case of haematopoietic stem cell transplant (HSCT) was
More informationNational Cancer Institute Research on Childhood Cancers. In the United States in 2005, approximately 9,510 children under age 15 will be
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s National Cancer Institute
More informationFertility Preservation in Women with Cancer. Objectives. Patient #1 10/24/2011. The audience will understand: How cancer therapy affects fertility.
Fertility Preservation in Women with Cancer Leslie R. DeMars Dartmouth-Hitchcock Medical Center Objectives The audience will understand: How cancer therapy affects fertility. Who should be considered for
More informationBREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine
Capecitabine Capecitabine 1000-1250mg/m 2 oral TWICE daily for 14 days Until disease progression Capecitabine + Docetaxel Capecitabine 750-1000mg/m 2 oral TWICE daily for 14 days Up to 6 cycles Capecitabine
More informationWhat is non-hodgkin lymphoma, how is it treated, and what is the unmet need?
What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,
More informationASWCS Policy for the Treatment of Extravasation Injury
ASWCS Policy for the Treatment of Extravasation Injury Extravasation of Cytotoxic Drugs Introduction 1. The purpose of this policy is to inform practitioners of their responsibilities in relation to preventing
More informationCHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located
More informationfor Extended Stability Parenteral Drugs Third Edition Caryn M. Bing, R.Ph., M.S., FASHP Editor
Extended Stability for Parenteral Drugs Third Edition Editor Caryn M. Bing, R.Ph., M.S., FASHP 1 American Society of Health-System Pharmacists Bethesda, Maryland Contents Preface Acknowledgments x/ Dedication
More informationCycle frequency: Every three weeks Total number of cycles: 3 or 4
BEP 3-day (Bleomycin/Etoposide/Cisplatin) Germ cell tumours Bleomycin 30,000iu 200mls N. Saline/30mins Days 2, 8 & 15 Etoposide 165mg/m 2 1L N. Saline/1hr Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/4hrs
More informationA 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
More informationAre CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
More informationNew Hampshire Childhood Cancer
Introduction: New Hampshire Childhood Cancer New Hampshire, Childhood Cancer, January 2009 Issue Brief Cancer in children is relatively uncommon, impacting fewer than twenty two of every 100,000 children
More informationCHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
More informationHighlights. www.lls.org Information Specialist: 800.955.4572. Psychological development. This publication was supported by a grant from
Long-Term and Late Effects of Treatment for Childhood Leukemia or Lymphoma Facts No. 15 in a series providing the latest information for patients, caregivers and healthcare professionals www.lls.org Information
More informationA Framework of Competences for the Level 3 Training Special Study Module in Paediatric Oncology
A Framework of Competences for the Level 3 Training Special Study Module in Paediatric Oncology Feb 2010 Royal College of Paediatrics and Child Health www.rcpch.ac.uk Royal College of Paediatrics and Child
More informationA Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly
Clinical Therapeutics/Volume 33, Number 3, 2011 A Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly Dimitrios C. Ziogas, MD 1,2 ; Michael
More informationBasics of Systemic Anticancer Therapy Prescribing and Verification
CHAPTER 2 Basics of Systemic Anticancer Therapy Prescribing and Verification Trinh Pham Joan Rivington Learning Objectives Upon completion of the chapter, the reader will be able to: 1. Write clear and
More informationDavid Loew, LCL MabThera
MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical
More informationNational Cancer Drugs Fund List Ver5.1
National Cancer Drugs Fund List Ver5.1 NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information Nursing Trans. & Corp. Ops. Commissioning Strategy Finance
More informationBendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line
More informationNational Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.
Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationSecond Cancers in Adults
Second Cancers in Adults This document focuses on second cancers in adults. For information about second cancers after treatment of childhood cancers, see our document Children Diagnosed With Cancer: Late
More informationAr Mino changes including adjustment of therapy algorithms
cute Myeloid Leukemia Updated April 2008 by Dr. Richard Wells* Updates: Ar Mino changes including adjustment of therapy algorithms Introduction Acute myeloid leukemia is a relatively uncommon cancer with
More informationBendamustine ADIS NEW DRUG PROFILE. Julia A. Barman Balfour and Karen L. Goa. Contents. Abstract
ADIS NEW DRUG PROFILE Drugs 2001; 61 (5): 631-638 0012-6667/01/0005-0631/$27.50/0 Adis International Limited. All rights reserved. Bendamustine Julia A. Barman Balfour and Karen L. Goa Adis International
More informationSynagis (Palivizumab)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationWaste Management Policy
Sharepoint Location Non-clinical Policies and Guidelines Sharepoint Index Directory 3.0 Corporate Sub Area 3.2 Trustwide Management Key words (for search purposes) Waste, Hazardous, Sharps, Household Central
More informationSecond Cancers Caused by Cancer Treatment
Second Cancers Caused by Cancer Treatment Advances in radiation therapy and chemotherapy have increased the chances of survival for many people with cancer today. People with cancer are often living longer,
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Upfront Therapy in Newly Diagnosed Elderly AML Patients: Is Decitabine (DAC) the new standard? Raoul Tibes, MD, PhD Senior Associate Consultant, Mayo Clinic Arizona Associate Director,
More informationEffective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm
Effective for dates of service on or after September 1, 2015, refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Uses of Monoclonal Antibodies for the Treatment of Non-Hodgkin
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationNetwork Activity and Clinical Audit Report
Managed Clinical Network for Haemato-oncology Network Activity and Clinical Audit Report June 2010 Dr Pam McKay Lead Clinician Heather Wotherspoon Network Manager Table of Contents ACKNOWLEDGEMENTS...
More informationAcute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma
Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma Updated April 2008 by Dr. Richard Wells* Updates: Minor changes only Introduction Acute lymphocytic leukemia (ALL) is a relatively
More informationCANCER TREATMENT PATHWAYS: AML A DETAILED COSTING STUDY EXAMPLE HAN-I WANG. PhD
CANCER TREATMENT PATHWAYS: AML A DETAILED COSTING STUDY EXAMPLE HAN-I WANG PhD 2010 CANCER TREATMENT PATHWAYS: AML A DETAILED COSTING STUDY EXAMPLE HAN-I WANG Submitted for the degree of Doctor of Philosophy
More informationCyrine-Eliana Haidar, Pharm.D., BCPS, BCOP; and Jennifer L. Pauley, Pharm.D., BCPS
Pediatric Leukemias Cyrine-Eliana Haidar, Pharm.D., BCPS, BCOP; and Jennifer L. Pauley, Pharm.D., BCPS Reviewed by Betsy Bickert Poon, Pharm.D.; Todd P. Semla, Pharm.D., M.S., FCCP, BCPS, AGSF; and Maya
More informationCHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER
CHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER INTRODUCTION This chapter provides an overview of treatment for small cell lung cancer (SCLC). Treatment options are presented based on the extent of disease.
More informationMichael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto
Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory
More informationChapter 4 Section 23.1. High Dose Chemotherapy (HDC) And Stem Cell Transplantation
Surgery Chapter 4 Section 23.1 High Dose Chemotherapy (HDC) And Stem Cell Transplantation Issue Date: November 1, 1983 Authority: 32 CFR 199.4(e)(5) and (g)(15) 1.0 CPT 1 PROCEDURE CODES 38205, 38207,
More informationThe AML Guide. Information for Patients and Caregivers. Acute Myeloid Leukemia. Emily, AML survivor
The AML Guide Information for Patients and Caregivers Acute Myeloid Leukemia Emily, AML survivor Revised 2012 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society
More informationDecember 4, 2014 Rebecca Johnson, MD Mary Bridge Hospital Tacoma, WA USA
Fertility preservation for AYAs December 4, 2014 Rebecca Johnson, MD Mary Bridge Hospital Tacoma, WA USA Aims Guidelines Barriers to implementation Assessment of risk Methods of preserving fertility Optimising
More informationCytotoxic Drug Contamination in Hospital and Municipal Wastewater and Its Transfer to Surface Water
Cytotoxic Drug Contamination in Hospital and Municipal Wastewater and Its Transfer to Surface Water Pharma-Cycle Inc. Theresa L. O'Keefe, Ph.D. Chief Scientific Officer September 21, 2011 Introduction
More informationAPPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen
APPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen Outline Diagnosis Prognosis Treatment AML Elderly AML APL Future directions AML
More informationMatthew Ulrickson, MD Banner MD Anderson Cancer Center July 29, 2015
Matthew Ulrickson, MD Banner MD Anderson Cancer Center July 29, 2015 Discuss the clinical presentation and diagnosis of acute leukemia * Discuss the impact of molecular features on prognosis and management
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007
More informationPROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA
2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationSmall cell Lung cancer New Chemotherapy options. Nicolas Mach, MD,PD
Small cell Lung cancer New Chemotherapy options Nicolas Mach, MD,PD > 40 negative Phase III trials List of unsucessful drugs Pemetrexed, imatinib, bevacizumab, bcl-2 antagonist, ASCT, CASE PRESENTATION
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation Document Title Clinical Management Protocol Children s Hepatic Tumours Document Date July 2010 Document Purpose Authors Modalities of treatment
More informationCOMMON CHILDHOOD CANCERS. PL Tan and TC Quah
COMMON CHILDHOOD CANCERS PL Tan and TC Quah In Singapore, approximately 1 in 600 children between ages 1 and 15 develops cancer and there are about 83 new cases a year of childhood cancer nationally. As
More informationChemotherapy for acute myeloid leukaemia
Chemotherapy for acute myeloid leukaemia This information is an extract from the booklet Understanding acute myeloid leukaemia. You may find the full booklet helpful. We can send you a free copy see page
More informationChildhood Non-Hodgkin Lymphoma
Understanding Childhood Non-Hodgkin Lymphoma A Guide for Patients, Survivors and Loved Ones First Edition Understanding Childhood Non-Hodgkin Lymphoma A Guide for Patients, Survivors and Loved Ones First
More informationKnee Pain in Patients With Cancer After Chemotherapy, Radiotherapy, and Bone Marrow Transplantation
Knee Pain in Patients With Cancer After Chemotherapy, Radiotherapy, and Bone Marrow Transplantation Eileen Chen, MD; Sajiv Sethi, BS; Adrienne Lee, BS; Anil Sethi, MD; Rahul Vaidya, MD abstract Full article
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationObjectives PREVENTION AND TREATMENT OF CINV & VTE IN ONCOLOGY PATIENTS. Case 1. Case 1. Case 2 2/1/2015
Objectives PREVENTION AND TREATMENT OF CINV & VTE IN ONCOLOGY PATIENTS Jennifer Gallanger, Pharm.D. Jennifer Kubert, Pharm.D. Pharmacy Practice Residents Providence Alaska Medical Center Discuss the pathophysiology
More information